GlassScriptPhysician profile
Lens Placide
NPI 1326780263
$4,580.24
in general payments reported to CMS, 2019-2025
23 companies · $1,916 in 2025
The $1,916 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $246 · 2023: $1,063 · 2024: $1,355 · 2025: $1,916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,298 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,297.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,025.00 | 2023-2025 | |
| Ucb, INC. | $579.20 | 2023-2025 | Zilbrysq, Briviact, Rystiggo |
| Emd Serono, INC. | $460.69 | 2023-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $429.06 | 2022-2024 | Ultomiris |
| Eisai INC. | $309.09 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $297.84 | 2024-2025 | |
| Genzyme Corporation | $196.37 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $184.22 | 2024-2025 | Ingrezza |
| Mdd US Operations, LLC | $160.95 | 2024-2025 | Apokyn |
| Biogen, INC. | $160.45 | 2022-2025 | Vumerity, Tysabri |
| Sk Life Science, INC. | $158.05 | 2023-2025 | |
| Genentech USA, INC. | $157.79 | 2024-2025 | Ocrevus Zunovo |
| Pfizer INC. | $71.00 | 2025 | |
| Acadia Pharmaceuticals INC | $70.65 | 2024-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $65.29 | 2025 | Crexont |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $52.93 | 2025 | Hyqvia |
| Lilly USA, LLC | $47.94 | 2024-2025 | Amyvid, Emgality, Kisunla |
| Jazz Pharmaceuticals INC. | $44.92 | 2025 | |
| Axsome Therapeutics, INC. | $32.28 | 2023 | Sunosi |
| Lundbeck LLC | $26.32 | 2024 | Vyepti |
| Tg Therapeutics, INC. | $23.65 | 2023 | |
| Amgen INC. | $16.54 | 2023 | Aimovig |
| Supernus Pharmaceuticals, INC. | $10.01 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lens Placide listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.